Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.81 |
| ▸ | FNTB | P49356 | 5/20 | 0.81 |
| ▸ | TSHR | P16473 | 4/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | AR | P10275 | 2/20 | 0.76 |
| ▸ | BLM | P54132 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SHBG | P04278 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.68 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403149 | 0.90 | FNTA (0.86) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL4105697 | 0.88 | FNTA (0.85) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL31249833 | 0.88 | FNTA (0.82) | FNTAFNTBTSHRNR3C1KMT2A | |
| Hydrochloric Acid SCHEMBL31249712 | 0.87 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL31249685 | 0.87 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL11432887 | 0.87 | FNTA (0.61) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL9819561 | 0.86 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL4501 | 0.86 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL9819556 | 0.86 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL10301195 | 0.86 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2026818-B1 | COMBINATION OF STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2010-12-22 | — | — | EP | claimed |
| US-7776846-B2 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2010-08-17 | — | — | US | claimed |
| EP-2026818-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | Bodor, Nicholas S. (US) | 2009-02-25 | — | — | EP | claimed |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR LABORATORIES, INC. | 2008-10-23 | — | — | US | claimed |
| US-7419971-B2 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2008-09-02 | — | — | US | claimed |
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | BODOR LABORATORIES, INC. | 2008-08-14 | — | — | US | claimed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | claimed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | claimed |
| EP-1658083-B1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR NICHOLAS S (US) | 2007-08-08 | — | — | EP | claimed |
| EP-1658083-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR, Nicholas S. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004112800-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR NICHOLAS S (US) | 2004-12-29 | — | — | WO | claimed |
| US-4970206-A | TRANSDERMAL DRUG DELIVERY | MERCK & CO., INC. (US) | 1990-11-13 | — | — | US | claimed |
| EP-1996710-B1 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | SALIX PHARMACEUTICALS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-2964196-A1 | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | Cipla Limited (IN) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | CIPLA LIMITED (MH) | 2016-01-07 | — | — | US | disclosed |
| US-4970206-A | TRANSDERMAL DRUG DELIVERY | MERCK & CO., INC. (US) | 1990-11-13 | — | — | US | disclosed |
| US-4847250-A | HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| US-4762851-A | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1988-08-09 | — | — | US | disclosed |
| EP-0227531-A2 | Pyroglutamic acid esters used as dermal penetration enhancers for drugs | MERCK & CO. INC. (US) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | HSD3B1, HSD3B2, HSD11B1 | FNTA 2562/4885FNTB 2540/4885TSHR 538/4885 |
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | SI, CROCC, FABP2 | FNTA 26/4885FNTB 36/4885TSHR 4689/4885 |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | HSD3B1, HSD11B1, EBP | FNTA 2220/4885FNTB 1187/4885TSHR 916/4885 |
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | NR3C1, NR3C2, HSD17B7 | FNTA 3307/4885FNTB 3123/4885TSHR 1903/4885 |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | NR3C1, NR3C2, HSD17B7 | FNTA 3307/4885FNTB 3123/4885TSHR 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.